gimli

RUBICON stock AI analysis

RUBICON Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

RUBICON RESEARCH LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available RUBICON price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive RUBICON stock page

Price

₹1,751.10

1W return

-2.17%

1M return

-2.94%

3M return

+33.95%

6M return

+128.04%

1Y return

n/a

Market cap

₹28,849.43 cr

116.93

22.38

ROE

+19.14%

ROCE

+13.09%

RSI

50.54

Turnover

₹82.37 cr

Why it can matter in screens

Momentum: RUBICON is above 50DMA, above 200DMA; RSI is 50.54.
Returns: 1D -1.53%, 1W -2.17%, 1M -2.94%, 3M +33.95%, 1Y n/a.
Trend levels: 52W high ₹1,899.00, 52W low ₹1,044.30, off high -7.79%.
Liquidity: latest turnover is ₹82.37 cr; volume vs 20D is +1.63%.
Valuation/profitability: PE 116.93, PB 22.38, ROE +19.14%, ROCE +13.09%.
Growth: 3Y sales CAGR +61.15%, 3Y profit CAGR n/a.

Quick Answers

What is the latest RUBICON stock price?

The latest stored price for RUBICON is Rs 1,751.10 as of 2026-09-18.

Is RUBICON above its 50DMA and 200DMA?

RUBICON is above 50DMA, above 200DMA. The latest 50DMA is 1,653.04 and the latest 200DMA is 1,073.90.

What are RUBICON PE, ROE and ROCE?

RUBICON has PE 116.93, ROE +19.14%, and ROCE +13.09% in Gimli's latest available snapshot.

How has RUBICON performed recently?

RUBICON has returned -2.94% over 1 month, +33.95% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	513.91 cr	121.31 cr	76.78 cr	4.66
2025-12-31	475.53 cr	111.91 cr	72.80 cr	4.46
2025-09-30	412.72 cr	94.99 cr	53.85 cr	3.47
2025-06-30	353.12 cr	79.74 cr	43.30 cr	2.79
2025-03-31	358.15 cr	72.57 cr	36.24 cr	2.20
2024-12-31	313.40 cr	70.39 cr	38.07 cr	2.31

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	1,753.96 cr	407.96 cr	246.74 cr	15.52
2025-03-31	1,284.27 cr	267.89 cr	167.54 cr	nan
2024-03-31	656.94 cr	99.55 cr	24.35 cr	1.58
2023-03-31	419.00 cr	43.97 cr	-16.89 cr	-1.11
2022-03-31	417.41 cr	57.45 cr	16.68 cr	32.91

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	2,326.71 cr	185.65 cr	311.01 cr	1,288.82 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	205.05 cr	-24.12 cr	n/a
2025-03-31	n/a	n/a	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-06-30	+59.76%	+7.52%	+9.43%	+7.23%	+23.30%	+0.00%
2026-03-31	+59.86%	+7.54%	+10.02%	+7.14%	+22.58%	+0.00%
2025-12-31	+59.99%	+7.99%	+9.45%	+6.61%	+22.57%	+0.00%
2025-10-15	+59.99%	+9.37%	+10.54%	+5.63%	+20.10%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze RUBICON RESEARCH with valuation, momentum and industry peers
Compare RUBICON with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.